ArticleHaematologica2024

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Josep-Maria Ribera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.